- Apa. 2000. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Text. Vol. Washington. American Psychiatric Association.
- Addington, Anjené M, and Judith L Rapoport. 2011. “Annual Research Review: Impact of Advances in Genetics in Understanding Developmental Psychopathology.” The Journal of Child Psychology and Psychiatry and Allied Disciplines 5 (5): 510–518.
- Buckholtz, J. W. and A. Meyer-Lindenberg (2012). "Psychopathology and the human connectome: toward a transdiagnostic model of risk for mental illness." Neuron 74(6): 990-1004.
- Cardno, A G, E J Marshall, B Coid, A M Macdonald, T R Ribchester, et al. 1999. “Heritability Estimates for Psychotic Disorders: The Maudsley Twin Psychosis Series.” Archives of General Psychiatry 56 (2): 162–168.
- Esslinger, C., H. Walter, P. Kirsch, S. Erk, K. Schnell, C. Arnold, L. Haddad, D. Mier, C. Opitz von Boberfeld, K. Raab, S. H. Witt, M. Rietschel, S. Cichon and A. Meyer-Lindenberg (2009). "Neural mechanisms of a genome-wide supported psychosis variant." Science 324(5927): 605.
- Faraone, SV, J Biederman, and E Mick. 2006. “The Age-dependent Decline of Attention Deficit Hyperactivity Disorder: a Meta-analysis of Follow-up Studies.” Psychol Med 36 (2): 159–65.
- Faraone, SV, RH Perlis, AE Doyle, JW Smoller, JJ Goralnick, et al. 2005. “Molecular Genetics of Attention-deficit/hyperactivity Disorder.” Biol Psychiatry 57 (11): 1313–23.
- Hyman, Steven E. 2010. “The Diagnosis of Mental Disorders: The Problem of Reification.” Ed. NolenHoeksema S And Cannon Td And Widiger T. Annual Review of Clinical Psychology 6 (December 2009): 155–179.
- Insel, Thomas, Bruce Cuthbert, Marjorie Garvey, Robert Heinssen, Daniel S Pine, et al. 2010. “Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders.” The American Journal of Psychiatry 167 (7): 748–751.
- Kendler, K S, M McGuire, A M Gruenberg, A O’Hare, M Spellman, and D Walsh. 1993. “The Roscommon Family Study. I. Methods, Diagnosis of Probands, and Risk of Schizophrenia in Relatives.” Archives of General Psychiatry 50 (7): 527–540.
- Kendler, K. S. (2013). What psychiatric genetics has taught us about the nature of psychiatric illness and what is left to learn. Molecular psychiatry, 18(10), 1058–66. doi:10.1038/mp.2013.50
- Kieseppä, Tuula, Timo Partonen, Jari Haukka, Jaakko Kaprio, and Jouko Lönnqvist. 2004. “High Concordance of Bipolar I Disorder in a Nationwide Sample of Twins.” The American Journal of Psychiatry 161 (10): 1814–1821.
- Krueger, R.F., and K.E. Markon. 2011. “A Dimensional-spectrum Model of Psychopathology: Progress and Opportunities.” Archives of General Psychiatry 68: 10–11.
- Linden, D. E. J. (2012). The Challenges and Promise of Neuroimaging in Psychiatry. Neuron, 73(1), 8–22.
- Meyer-Lindenberg, A. (2010). "From maps to mechanisms through neuroimaging of schizophrenia." Nature 468(7321): 194-202.
- Purcell, Shaun M, Naomi R Wray, Jennifer L Stone, Peter M Visscher, Michael Conlon O’Donovan, et al. 2009. “Common Polygenic Variation Contributes to Risk of Schizophrenia and Bipolar Disorder.” Nature 460 (7256): 748–752.
- Schwarz, E., NJ. VanBeveren, PC. Guest, R. Izmailov, and S. Bahn. 2011. “The Application of Multiplexed Assay Systems for Molecular Diagnostics.” Int Rev Neurobiol. 101: 259–78.
- Schwarz, E, PC Guest, J Steiner, B Bogerts, and S Bahn. 2012. “Identi?cation of Blood-based Molecular Signatures for Prediction of Response and Relapse.pdf.” Transl Psychiatry 2 (e82).
- Todd, R D. 2000. “Genetics of Attention Deficit/hyperactivity Disorder: Are We Ready for Molecular Genetic Studies?” American Journal of Medical Genetics 96 (3): 241–243.
- Wittchen, Hans-Ulrich, and Frank Jacobi. 2005. “Size and Burden of Mental Disorders in Europe--a Critical Review and Appraisal of 27 Studies.” European Neuropsychopharmacology the Journal of the European College of Neuropsychopharmacology 15 (4): 357–376.
- Wittchen, H U, F Jacobi, J Rehm, A Gustavsson, M Svensson, B Jönsson, J Olesen, et al. 2011. “The Size and Burden of Mental Disorders and Other Disorders of the Brain in Europe 2010.” European Neuropsychopharmacology the Journal of the European College of Neuropsychopharmacology 21 (9): 655–679. http://www.ncbi.nlm.nih.gov/pubmed/21896369.
Psychiatric disorders are well known to have a significant heritable component and this has been demonstrated conclusively in family, twin and adoption studies. Despite this, it has proven difficult to identify any individual or multiple biologically linked genetic parameters that explain a substantial proportion of this heritable variance.
Modern genetics technology allows characterization of genetic variants across the entire human genome. These approaches have not only confirmed the role of genetic factors for risk of psychiatric disorders and highlighted the fact that such risk is likely conferred by a multitude of factors with small individual effects, but also demonstrated that a substantial portion of genetic risk is shared between different psychiatric illnesses (Kendler, 2013).
While some of the illness linked variants were found to aggregate in certain biological pathways, it is currently not possible to predict genetic illness risk at the individual patient level to an extent that would be useful clinically. IMAGEMEND, however, has a clear multi-modal focus, aiming to integrate genetic readouts with those of brain structure and function as well as those of environmental risk. This will give an unprecedented opportunity to bridge the gap between genetic underpinning, environmental influences and alterations at the neural systems level and may lead to a new generation of clinical tools to aid in the clinical management of psychiatric illnesses.
The IMAGEMEND consortium is also in an ideal position to evaluate the alignment of such illness-associated, multi-modal biological patterns with currently established diagnostic constructs, which may uncover biologically defined and potentially trans-diagnostic subgroups of patients and highlight biological mechanisms that may be the basis for development of novel therapeutics.
It is widely believed that psychiatric illnesses are disorders of the brain. In the past 30 years many neuroimaging techniques have been successfully developed to investigate the brain of the living patient. Among those, magnetic resonance imaging (MRI) represents a unique noninvasive technology for imaging of brain structure and function without exposing patients to potentially harmful radiation. Structural MRI quantifies shape and size of brain structures while functional MRI explores differences in brain blood oxygenation as an indirect readout of activity.
Studies that have used MRI technology extensively reported both structural and functional alterations in various psychiatric disorders. However, these brain alterations are subtle and distributed in nature, thus limiting the utility of MRI in the clinical management of these disorders. IMAGEMEND will attempt to address this problem through statistical integration of neuroimaging data with genetic, clinic and environmental data in order to obtain “multimodal profiles” to differentiate diagnosis and predict the course of psychiatric illnesses.
Finally, IMAGEMEND will be utilizing neuroimaging technology to advance the development of a real-time functional MRI based neurofeedback that represents an entirely new treatment modality for psychiatric disorders. Specifically, using this integrated imaging system, patients will be able to directly and non-invasively modify illness relevant brain circuits. This will open a new avenue for psychiatric intervention in addition to the currently available pharmacotherapy and psychotherapy.
Despite the broad availability of neuroimaging facilities such as MRI and their vast utilization to study psychiatric disorders, no neuroimaging applications have reached clinical practice in psychiatry except for excluding somatic, especially neurological disorders and quantification of atrophies in some dementias. In general, no diagnostic of predictive test for psychiatric disorders has reached clinical practice. This also includes genetic tests, which have, despite the volume of genome-wide association studies performed on patients with schizophrenia and bipolar disorder, insufficient classification performance to be useful for individual subject predictions. IMAGEMEND is targeted at the development of diagnostic and predictive tools aimed at several central issues in clinical management of mental illness and addresses an enormous public heath need. Specifically, an objective tool to discriminate schizophrenia, bipolar disorder and ADHD is especially in early disease phases are urgently required for more accurate differential diagnosis. Similarly, a neuroimaging tool to predict response and side-effect occurrence would be invaluable in clinical practice to objectify the process of treatment selection and achieve better patient outcomes through stratification at the biological level.
